Monje M, Borniger JC, D’Silva NJ, Deneen B, Dirks PB, Fattahi F, et al. Roadmap for the emerging field of cancer neuroscience. Cell. 2020;181:219–22.
Google Scholar
Shi DD, Guo JA, Hoffman HI, Su J, Mino-Kenudson M, Barth JL, et al. Therapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunities. Lancet Oncol. 2022;23:e62–e74.
Google Scholar
Ayala GE, Dai H, Powell M, Li R, Ding Y, Wheeler TM, et al. Cancer-related axonogenesis and neurogenesis in prostate cancer. Clin Cancer Res. 2008;14:7593–603.
Google Scholar
Zahalka AH, Arnal-Estape A, Maryanovich M, Nakahara F, Cruz CD, Finley LWS, et al. Adrenergic nerves activate an angio-metabolic switch in prostate cancer. Science. 2017;358:321–6.
Google Scholar
March B, Faulkner S, Jobling P, Steigler A, Blatt A, Denham J, et al. Tumour innervation and neurosignalling in prostate cancer. Nat Rev Urol. 2020;17:119–30.
Google Scholar
Magnon C, Hall SJ, Lin J, Xue X, Gerber L, Freedland SJ, et al. Autonomic nerve development contributes to prostate cancer progression. Science. 2013;341:1236361.
Google Scholar
Di Donato M, Giovannelli P, Migliaccio A, Castoria G. The nerve growth factor-delivered signals in prostate cancer and its associated microenvironment: when the dialogue replaces the monologue. Cell Biosci. 2023;13:60.
Google Scholar
Kfoury Y, Baryawno N, Severe N, Mei S, Gustafsson K, Hirz T, et al. Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment. Cancer Cell. 2021;39:1464–78.e1468.
Google Scholar
Brea L, Yu J. Tumor-intrinsic regulators of the immune-cold microenvironment of prostate cancer. Trends Endocrinol Metab. 2025;36:855–66.
Google Scholar
Coarfa C, Florentin D, Putluri N, Ding Y, Au J, He D, et al. Influence of the neural microenvironment on prostate cancer. Prostate. 2018;78:128–39.
Google Scholar
Sigorski D, Kasprzyk-Pawelec A, Michalak M, Sosnowski R, Hryciuk MM, Sejda A, et al. The nervous system in prostate cancer: a basic science and clinical perspective. Semin Oncol. 2026;53:152425.
Google Scholar
Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol. 2018;36:2492–503.
Google Scholar
Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell. 2017;32:474–89.e476.
Google Scholar
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152–60.
Google Scholar
Zou M, Toivanen R, Mitrofanova A, Floch N, Hayati S, Sun Y, et al. Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate cancer. Cancer Discov. 2017;7:736–49.
Google Scholar
Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, et al. N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer. Cancer Cell. 2016;30:563–77.
Google Scholar
Lee JK, Phillips JW, Smith BA, Park JW, Stoyanova T, McCaffrey EF, et al. N-Myc drives neuroendocrine prostate cancer initiated from human prostate epithelial cells. Cancer Cell. 2016;29:536–47.
Google Scholar
Park JW, Lee JK, Sheu KM, Wang L, Balanis NG, Nguyen K, et al. Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. Science. 2018;362:91–95.
Google Scholar
Li Q, Deng Q, Chao HP, Liu X, Lu Y, Lin K, et al. Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Nat Commun. 2018;9:3600.
Google Scholar
Wang HT, Yao YH, Li BG, Tang Y, Chang JW, Zhang J. Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis. J Clin Oncol. 2014;32:3383–90.
Google Scholar
Vanden Abeele F, Salzet M. The neuro-immune oncology axis. Cancer Lett. 2025;634:218070.
Google Scholar
Liu Z, Peng Q, Wang Y, Chiu PK, Teoh JY, Wang R, et al. Neuroscience in prostate cancer. Prostate Cancer Prostatic Dis. 2026;29:478–87.
Venkatesh HS, Tam LT, Woo PJ, Lennon J, Nagaraja S, Gillespie SM, et al. Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. Nature. 2017;549:533–7.
Google Scholar
Aysit N, Altintas E, Koksalar Alkan F, Ozturk G, Korkaya H. The neural niche in cancer: mechanistic insights into tumor-neuron-immune crosstalk and therapeutic opportunities. Front Cell Dev Biol. 2026;14:1667459.
Google Scholar
Gandhi S, Pandey MR, Attwood K, Ji W, Witkiewicz AK, Knudsen ES, et al. Phase I clinical trial of combination propranolol and pembrolizumab in locally advanced and metastatic melanoma: safety, tolerability, and preliminary evidence of antitumor activity. Clin Cancer Res. 2021;27:87–95.
Google Scholar
Klose CSN, Mahlakoiv T, Moeller JB, Rankin LC, Flamar AL, Kabata H, et al. The neuropeptide neuromedin U stimulates innate lymphoid cells and type 2 inflammation. Nature. 2017;549:282–6.
Google Scholar
Li Y, Liu S, Zhou K, Wang Y, Chen Y, Hu W, et al. Neuromedin U programs eosinophils to promote mucosal immunity of the small intestine. Science. 2023;381:1189–96.
Google Scholar
Moriyama M, Sato T, Inoue H, Fukuyama S, Teranishi H, Kangawa K, et al. The neuropeptide neuromedin U promotes inflammation by direct activation of mast cells. J Exp Med. 2005;202:217–24.
Google Scholar
Martinez VG, O’Driscoll L. Neuromedin U: a multifunctional neuropeptide with pleiotropic roles. Clin Chem. 2015;61:471–82.
Google Scholar
Dcunha L, Edakkad B, Fathima I, Dagamajalu S, Raju R, Devasahayam Arokia Balaya R, et al. Neuromedin U signaling map: toward neuropeptide focused therapeutic targets in cancer and human diseases. OMICS. 2026;30:211–23.
Google Scholar
Malendowicz LK, Rucinski M. Neuromedins NMU and NMS: an updated overview of their functions. Front Endocrinol. 2021;12:713961.
Google Scholar
Raddatz R, Wilson AE, Artymyshyn R, Bonini JA, Borowsky B, Boteju LW, et al. Identification and characterization of two neuromedin U receptors differentially expressed in peripheral tissues and the central nervous system. J Biol Chem. 2000;275:32452–9.
Google Scholar
Przygodzka P, Soboska K, Sochacka E, Boncela J. Neuromedin U: a small peptide in the big world of cancer. Cancers. 2019;11:1312.
Google Scholar
Benzaquen D, Lawrence YR, Taussky D, Zwahlen D, Oehler C, Champion A. The crosstalk between nerves and cancer-A poorly understood phenomenon and new possibilities. Cancers. 2024;16:1875.
Google Scholar
Przygodzka P, Szulc-Kielbik I, Kielbik M, Pacholczyk M, Klink M. Neuromedin U in the tumor microenvironment – Possible actions in tumor progression. Biochim Biophys Acta Rev Cancer. 2025;1880:189269.
Google Scholar
Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21.
Google Scholar
Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinforma. 2011;12:323.
Google Scholar
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.
Google Scholar
Berman-Booty LD, Sargeant AM, Rosol TJ, Rengel RC, Clinton SK, Chen CS, et al. A review of the existing grading schemes and a proposal for a modified grading scheme for prostatic lesions in TRAMP mice. Toxicol Pathol. 2012;40:5–17.
Google Scholar
Zaidi S, Park J, Chan JM, Roudier MP, Zhao JL, Gopalan A, et al. Single cell analysis of treatment-resistant prostate cancer: implications of cell state changes for cell surface antigen targeted therapies. Proc Natl Acad Sci USA. 2024;121:e2322203121.
Google Scholar
Labrecque MP, Coleman IM, Brown LG, True LD, Kollath L, Lakely B, et al. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J Clin Invest. 2019;129:4492–505.
Google Scholar
Zheng Q, Xie X, Guo Q, Chen C, Jiang W. Prognostic value of tumor-infiltrating lymphocytes and common subtypes in patients with gastroenteropancreatic neuroendocrine neoplasms: a systematic review and meta-analysis. BMC Cancer. 2026;26:793.
Google Scholar
Yeung AML, Chow JCH. Management of pulmonary large-cell neuroendocrine carcinoma (LCNEC): an updated review. Clin Lung Cancer. 2026;27:85–97.
Google Scholar
Chen D, Ayala GE. Innervating prostate cancer. N Engl J Med. 2018;378:675–7.
Google Scholar
Dysthe M, Parihar R. Myeloid-derived suppressor cells in the tumor microenvironment. Adv Exp Med Biol. 2020;1224:117–40.
Google Scholar
Brower V. Tasquinimod treatment for prostate cancer. Lancet Oncol. 2016;17:e322.
Google Scholar
Moriyama M, Fukuyama S, Inoue H, Matsumoto T, Sato T, Tanaka K, et al. The neuropeptide neuromedin U activates eosinophils and is involved in allergen-induced eosinophilia. Am J Physiol Lung Cell Mol Physiol. 2006;290:L971–977.
Google Scholar
Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162–74.
Google Scholar
Przygodzka P, Soboska K, Sochacka E, Pacholczyk M, Braun M, Kassassir H, et al. Neuromedin U secreted by colorectal cancer cells promotes a tumour-supporting microenvironment. Cell Commun Signal. 2022;20:193.
Google Scholar
Johnson EN, Appelbaum ER, Carpenter DC, Cox RF, Disa J, Foley JJ, et al. Neuromedin U elicits cytokine release in murine Th2-type T cell clone D10.G4.1. J Immunol. 2004;173:7230–8.
Google Scholar
Zheng R, Wang S, Wang J, Zhou M, Shi Q, Liu B. Neuromedin U regulates the anti-tumor activity of CD8(+) T cells and glycolysis of tumor cells in the tumor microenvironment of pancreatic ductal adenocarcinoma in an NMUR1-dependent manner. Cancer Sci. 2024;115:334–46.
Google Scholar
Zhou Y, Zhang X, Gao Y, Peng Y, Liu P, Chen Y, et al. Neuromedin U receptor 1 deletion leads to impaired immunotherapy response and high malignancy in colorectal cancer. iScience. 2024;27:110318.
Google Scholar
Chen Y, Ouyang Y, Li Z, Wang X, Ma J. S100A8 and S100A9 in cancer. Biochim Biophys Acta Rev Cancer. 2023;1878:188891.
Google Scholar
Eisenblaetter M, Flores-Borja F, Lee JJ, Wefers C, Smith H, Hueting R, et al. Visualization of tumor-immune interaction – target-specific imaging of S100A8/A9 reveals pre-metastatic niche establishment. Theranostics. 2017;7:2392–401.
Google Scholar
Sprenkeler EGG, Zandstra J, van Kleef ND, Goetschalckx I, Verstegen B, Aarts CEM, et al. S100A8/A9 is a marker for the release of neutrophil extracellular traps and induces neutrophil activation. Cells. 2022;11:236.
Google Scholar
Silvin A, Chapuis N, Dunsmore G, Goubet AG, Dubuisson A, Derosa L, et al. Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19. Cell. 2020;182:1401–18.e1418.
Google Scholar
Wu R, Duan L, Cui F, Cao J, Xiang Y, Tang Y, et al. S100A9 promotes human hepatocellular carcinoma cell growth and invasion through RAGE-mediated ERK1/2 and p38 MAPK pathways. Exp Cell Res. 2015;334:228–38.
Google Scholar
Yang Q, Li X, Chen H, Cao Y, Xiao Q, He Y, et al. IRF7 regulates the development of granulocytic myeloid-derived suppressor cells through S100A9 transrepression in cancer. Oncogene. 2017;36:2969–80.
Google Scholar
Kwak T, Wang F, Deng H, Condamine T, Kumar V, Perego M, et al. Distinct populations of immune-suppressive macrophages differentiate from monocytic myeloid-derived suppressor cells in cancer. Cell Rep. 2020;33:108571.
Google Scholar
Maus RLG, Jakub JW, Nevala WK, Christensen TA, Noble-Orcutt K, Sachs Z, et al. Human melanoma-derived extracellular vesicles regulate dendritic cell maturation. Front Immunol. 2017;8:358.
Google Scholar
Zhou L, Wang M, Guo H, Hou J, Zhang Y, Li M, et al. Integrated analysis highlights the immunosuppressive role of TREM2(+) macrophages in hepatocellular carcinoma. Front Immunol. 2022;13:848367.
Google Scholar
Sade-Feldman M, Kanterman J, Ish-Shalom E, Elnekave M, Horwitz E, Baniyash M. Tumor necrosis factor-alpha blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity. 2013;38:541–54.
Google Scholar
Ittmann M, Huang J, Radaelli E, Martin P, Signoretti S, Sullivan R, et al. Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res. 2013;73:2718–36.
Google Scholar
Hensley PJ, Kyprianou N. Modeling prostate cancer in mice: limitations and opportunities. J Androl. 2012;33:133–44.
Google Scholar
Irshad S, Abate-Shen C. Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic. Cancer Metastasis Rev. 2013;32:109–22.
Google Scholar
de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41:374–403.
Google Scholar
Chia K, Mazzolini J, Mione M, Sieger D. Tumor initiating cells induce Cxcr4-mediated infiltration of pro-tumoral macrophages into the brain. Elife. 2018;7:e31918.
Google Scholar
Linde N, Casanova-Acebes M, Sosa MS, Mortha A, Rahman A, Farias E, et al. Macrophages orchestrate breast cancer early dissemination and metastasis. Nat Commun. 2018;9:21.
Google Scholar
Asano K, Takahashi N, Ushiki M, Monya M, Aihara F, Kuboki E, et al. Intestinal CD169(+) macrophages initiate mucosal inflammation by secreting CCL8 that recruits inflammatory monocytes. Nat Commun. 2015;6:7802.
Google Scholar
Schlesinger Y, Yosefov-Levi O, Kolodkin-Gal D, Granit RZ, Peters L, Kalifa R, et al. Single-cell transcriptomes of pancreatic preinvasive lesions and cancer reveal acinar metaplastic cells’ heterogeneity. Nat Commun. 2020;11:4516.
Google Scholar
Bhinder B, Ferguson A, Sigouros M, Uppal M, Elsaeed AG, Bareja R, et al. Immunogenomic landscape of neuroendocrine prostate cancer. Clin Cancer Res. 2023;29:2933–43.
Google Scholar
Romero R, Chu T, Gonzalez Robles TJ, Smith P, Xie Y, Kaur H, et al. The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1. Nat Cancer. 2024;5:1641–59.
Google Scholar
Goswami S, Aparicio A, Subudhi SK. Immune checkpoint therapies in prostate cancer. Cancer J. 2016;22:117–20.
Google Scholar
Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M, et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature. 2018;559:363–9.
Google Scholar
Jachetti E, Cancila V, Rigoni A, Bongiovanni L, Cappetti B, Belmonte B, et al. Cross-talk between myeloid-derived suppressor cells and mast cells mediates tumor-specific immunosuppression in prostate cancer. Cancer Immunol Res. 2018;6:552–65.
Google Scholar
Guo C, Sharp A, Gurel B, Crespo M, Figueiredo I, Jain S, et al. Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance. Nature. 2023;623:1053–61.
Google Scholar
Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002;62:1832–7.
Google Scholar
Li J, Zhang L, Liu R, Xu C, Tang H, Zou Y, et al. CXCL12/CXCR4 axis governs Treg spatial dominance over CD8+ T cells via IL-2 sequestration: a dual therapeutic target in prostate cancer. Front Immunol. 2025;16:1626708.
Google Scholar
Raymond E, Dalgleish A, Damber JE, Smith M, Pili R. Mechanisms of action of tasquinimod on the tumour microenvironment. Cancer Chemother Pharm. 2014;73:1–8.
Google Scholar
Siddiqui I, Schaeuble K, Chennupati V, Fuertes Marraco SA, Calderon-Copete S, Pais Ferreira D, et al. Intratumoral Tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity. 2019;50:195–211.e110.
Google Scholar
Cullen SP, Brunet M, Martin SJ. Granzymes in cancer and immunity. Cell Death Differ. 2010;17:616–23.
Google Scholar
Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, et al. Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019;20:326–36.
Google Scholar
Pili R, Haggman M, Stadler WM, Gingrich JR, Assikis VJ, Bjork A, et al. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol. 2011;29:4022–8.
Google Scholar
Sternberg C, Armstrong A, Pili R, Ng S, Huddart R, Agarwal N, et al. Randomized, double-blind, placebo-controlled phase III study of tasquinimod in men with metastatic castration-resistant prostate cancer. J Clin Oncol. 2016;34:2636–43.
Google Scholar
Lyu A, Fan Z, Clark M, Lea A, Luong D, Setayesh A, et al. Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. Nature. 2025;637:1207–17.
Google Scholar
